Community Clinical Research Joins PhaseWell Research to Anchor Inpatient CNS Capabilities and Expand Clinical Trial Access Across Austin and Broader Texas Region
PhaseWell Research (“PhaseWell”), a multisite clinical research company, today announced its partnership with Community Clinical Research (“CCR”) in Austin, Texas. With the help of co-founder Kris Brown, Dr. David Brown, Principal Investigator, has over the past 30 years assembled a highly focused, expert research team. Led by Dr. Brown and guided in business development by Janice Roggenkamp, CCR has established itself as one of the most experienced inpatient-capable CNS research sites in the country. The partnership advances PhaseWell’s mission of connecting communities to clinical trials, bringing hope today and shaping tomorrow’s medicine.
Latin Clinical Trial Center joins PhaseWell Research to Expand Clinical Trial Access and Therapeutic Reach in Puerto Rico
PhaseWell Research (“PhaseWell”), a multisite clinical research company, today announced its partnership with Latin Clinical Trial Center (“LCTC”) in San Juan, Puerto Rico. Led by founder and Principal Investigator Dr. Carlos A. Sariol and Site Leader Anmari Ferrer, LCTC is widely recognized as one of Puerto Rico’s foremost clinical research sites, with two decades of continuous operation and a track record spanning more than 85 clinical studies across Phase II–IV. The partnership further expands PhaseWell’s mission of connecting communities to clinical trials, bringing hope today and shaping tomorrow’s medicine.
PhaseWell Research Acquires Chase Medical Research to Expand Clinical Trial Capabilities in Connecticut
PhaseWell Research (“PhaseWell”), a multisite clinical research company, today announced the strategic acquisition of Chase Medical Research (“CMR”). Under the leadership of founder, key opinion leader, and lead Principal Investigator Dr. Joseph Soufer, CMR operates sites in Waterbury and Hamden, Connecticut. The partnership supports PhaseWell’s mission of connecting communities to clinical trials, bringing hope today and shaping tomorrow’s medicine.
Bio Behavioral Health Joins PhaseWell Research to Expand Access to Neuropsychiatric Clinical Trials
PhaseWell Research (“PhaseWell”), a national clinical research site company, today announced a new partnership with Bio Behavioral Health (“BBH”), a leading central nervous system (CNS) research site focused in neurologic and psychiatric disorders. The partnership reflects PhaseWell’s continued commitment to connecting communities to clinical trials, bringing hope today and shaping tomorrow’s medicine.
